AbbVie provides update on Phase 2 results for Emraclidine in schizophrenia

Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial

Shilpa Medicare’s acceptance by USFDA of NDA filed by its CDMO partner Unicycive for Oxylanthanum Carbonate

Alembic receives USFDA final approval for Diltiazem Hydrochloride ER capsules

Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension

Pfizer INDovation program boosts six start-ups with Rs. 1.5 crore grant

The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring

Lupin receives tentative approval from USFDA for Raltegravir Tablets

This product will be manufactured at Lupin’s Nagpur facility in India

Mitsui Chemicals invests in clinical kidney disease drug developer Rege Nephro

The company uses iPS cells to develop treatments for diseases relating to the kidney

KIMS to acquire 3,000 beds in next 5 years in Kerala

The group plans to establish new hospitals in Kerala developing large health cities in Kochi and Kozhikode

Mitsui Chemicals begins sale of i-TFC luminous II dental material range

The new range incorporates a product that also contains the S-PRG filler employed in the Giomer range

Ichnos Glenmark Innovation to present Phase 1 study of Trispecific ISB 2001 in r/rMM at ASH Annual Meeting

ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM

Lonza’s Synaffix collaborates with BigHat Biosciences for ML-designed ADC

Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies